Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 21-22/2021

15.09.2021 | original article

Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer

A retrospective Austrian multicenter study

verfasst von: Sabine Geiger-Gritsch, Horst Olschewski, Florian Kocher, Robert Wurm, Gudrun Absenger, Martin Flicker, André Hermann, Peter Heininger, Michael Fiegl, Melanie Zechmeister, Florian Endel, Claudia Wild, Georg Pall

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 21-22/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Objective

As real-world data regarding immunotherapy for non-small cell lung cancer are lacking for Austria, we conducted a retrospective study in six hospitals to present data from real-world practice.

Methods

Patients with metastatic non-small cell lung cancer were stratified into two groups, either patients with first-line pembrolizumab monotherapy (cohort 1) or patients with second-line nivolumab, pembrolizumab or atezolizumab monotherapy (cohort 2). Primary outcome measures were objective response rate and overall survival. A matched-pair analysis was performed to compare overall survival to patients from the Tyrolean Lung Cancer Project as a historical control group.

Results

In total, 89 patients were identified, 42 patients in cohort 1 and 47 patients in cohort 2. The objective response rates were 43.3% and 31.4%, respectively. The median overall survival was 17.0 months (95% CI 11.7–21.5 months) in cohort 1 and 18.7 months (95% CI 9.5–23.4 months) in cohort 2. Treatment-related adverse events grades 3 and 4 were reported in 11.2% of patients. The matched-pair analysis showed a median overall survival of 15.2 months (95% CI 7.6–20.4 months) for first-line pembrolizumab monotherapy compared to 9.8 months (95% CI 7.8–11.6 months) for the historical control (p = 0.43). In cohort 2, a median overall survival of 20.3 months (95% CI 6.9–26.2 months) for second-line immunotherapy compared to 5.4 months (95% CI 3.2–11.7 months) for the historical control (p = 0.18) was shown.

Conclusion

The results are comparable with other real-world studies and, when matched to historical controls, support the improvement in outcomes made possible by these agents.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. CrossRef Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. CrossRef
2.
Zurück zum Zitat Brahmer J, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35. CrossRef Brahmer J, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35. CrossRef
3.
Zurück zum Zitat Herbst RS, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. CrossRef Herbst RS, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. CrossRef
4.
Zurück zum Zitat Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. CrossRef Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. CrossRef
5.
Zurück zum Zitat Reck M, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50 % or greater. J Clin Oncol. 2019;37(7):537–46. CrossRef Reck M, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50 % or greater. J Clin Oncol. 2019;37(7):537–46. CrossRef
6.
Zurück zum Zitat Rittmeyer A, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65. CrossRef Rittmeyer A, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65. CrossRef
7.
Zurück zum Zitat Berger ML, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Value Health. 2017;20(8):1003–8. CrossRef Berger ML, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Value Health. 2017;20(8):1003–8. CrossRef
8.
Zurück zum Zitat Chan K, et al. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian real-world evidence for value of cancer drugs (CanREvalue) collaboration. BMJ Open. 2020;10(1):e32884. CrossRef Chan K, et al. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian real-world evidence for value of cancer drugs (CanREvalue) collaboration. BMJ Open. 2020;10(1):e32884. CrossRef
9.
Zurück zum Zitat de Lusignan S, Crawford L, Munro N. Creating and using real-world evidence to answer questions about clinical effectiveness. J Innov Health Inform. 2015;22(3):368–73. CrossRef de Lusignan S, Crawford L, Munro N. Creating and using real-world evidence to answer questions about clinical effectiveness. J Innov Health Inform. 2015;22(3):368–73. CrossRef
10.
Zurück zum Zitat Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295–304. CrossRef Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295–304. CrossRef
12.
Zurück zum Zitat Oyinlola JO, Campbell J, Kousoulis AA. Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances. BMC Health Serv Res. 2016;16:299. CrossRef Oyinlola JO, Campbell J, Kousoulis AA. Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances. BMC Health Serv Res. 2016;16:299. CrossRef
13.
Zurück zum Zitat Goldstraw P, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. CrossRef Goldstraw P, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. CrossRef
15.
Zurück zum Zitat Seymour L, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e52. CrossRef Seymour L, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e52. CrossRef
16.
Zurück zum Zitat Kocher F, et al. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. Cancer Treat Res. 2015;87(2):193–200. Kocher F, et al. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. Cancer Treat Res. 2015;87(2):193–200.
17.
Zurück zum Zitat R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.
21.
Zurück zum Zitat Planchard D, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):863–70. CrossRef Planchard D, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):863–70. CrossRef
22.
Zurück zum Zitat Postmus PE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):iv1–iv21. CrossRef Postmus PE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):iv1–iv21. CrossRef
24.
Zurück zum Zitat Mok TSK, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30. CrossRef Mok TSK, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30. CrossRef
25.
Zurück zum Zitat Faehling M, et al. Immuno-oncological treatment and tumor mass in non-small cell lung cancer: case-control analysis of overall survival in routine clinical practice. Oncology. 2019;97(4):228–35. CrossRef Faehling M, et al. Immuno-oncological treatment and tumor mass in non-small cell lung cancer: case-control analysis of overall survival in routine clinical practice. Oncology. 2019;97(4):228–35. CrossRef
26.
Zurück zum Zitat Ahn BC, et al. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD‑1 therapy in real-world practice. J Cancer Res Clin Oncol. 2019;145(6):1613–23. CrossRef Ahn BC, et al. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD‑1 therapy in real-world practice. J Cancer Res Clin Oncol. 2019;145(6):1613–23. CrossRef
27.
Zurück zum Zitat Areses Manrique MC, et al. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Transl Lung Cancer Res. 2018;7(3):404–15. CrossRef Areses Manrique MC, et al. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Transl Lung Cancer Res. 2018;7(3):404–15. CrossRef
28.
Zurück zum Zitat Dudnik E, et al. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data. Cancer Treat Res. 2018;126:217–23. Dudnik E, et al. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data. Cancer Treat Res. 2018;126:217–23.
29.
Zurück zum Zitat Juergens RA, et al. Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort. Curr Oncol. 2018;25(6):384–92. CrossRef Juergens RA, et al. Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort. Curr Oncol. 2018;25(6):384–92. CrossRef
30.
Zurück zum Zitat Khozin S, et al. Real-world outcomes of patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following U.S. regulatory approval. Oncologist. 2019;24(5):648–56. CrossRef Khozin S, et al. Real-world outcomes of patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following U.S. regulatory approval. Oncologist. 2019;24(5):648–56. CrossRef
31.
Zurück zum Zitat Kobayashi K, et al. Real-world efficacy and safety of nivolumab for advanced non-small-cell lung cancer: a retrospective multicenter analysis. Clin Lung Cancer. 2018;19(3):e349–e58. CrossRef Kobayashi K, et al. Real-world efficacy and safety of nivolumab for advanced non-small-cell lung cancer: a retrospective multicenter analysis. Clin Lung Cancer. 2018;19(3):e349–e58. CrossRef
33.
Zurück zum Zitat Mazieres J, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;24:24. Mazieres J, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;24:24.
34.
Zurück zum Zitat Merino Almazan M, et al. A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice. Int J Clin Pharm. 2019;41(1):272–9. CrossRef Merino Almazan M, et al. A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice. Int J Clin Pharm. 2019;41(1):272–9. CrossRef
36.
Zurück zum Zitat Weis TM, et al. Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy. J Oncol Pharm Pract. 2020;26(3):564–71. CrossRef Weis TM, et al. Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy. J Oncol Pharm Pract. 2020;26(3):564–71. CrossRef
38.
Zurück zum Zitat Bjornhart B, et al. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncol. 2019;58(7):953–61. CrossRef Bjornhart B, et al. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncol. 2019;58(7):953–61. CrossRef
39.
Zurück zum Zitat Ksienski D, et al. Pembrolizumab for advanced nonsmall cell lung cancer: efficacy and safety in everyday clinical practice. Cancer Treat Res. 2019;133:110–6. Ksienski D, et al. Pembrolizumab for advanced nonsmall cell lung cancer: efficacy and safety in everyday clinical practice. Cancer Treat Res. 2019;133:110–6.
40.
Zurück zum Zitat Tamiya M, et al. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50 % PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). Invest New Drugs. 2019;37(6):1266–73. CrossRef Tamiya M, et al. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50 % PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). Invest New Drugs. 2019;37(6):1266–73. CrossRef
41.
Zurück zum Zitat Wang Y, et al. Treatment-related adverse events of PD‑1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008–19. CrossRef Wang Y, et al. Treatment-related adverse events of PD‑1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008–19. CrossRef
Metadaten
Titel
Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer
A retrospective Austrian multicenter study
verfasst von
Sabine Geiger-Gritsch
Horst Olschewski
Florian Kocher
Robert Wurm
Gudrun Absenger
Martin Flicker
André Hermann
Peter Heininger
Michael Fiegl
Melanie Zechmeister
Florian Endel
Claudia Wild
Georg Pall
Publikationsdatum
15.09.2021
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 21-22/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-021-01940-w